Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Advanced Cutaneous T-cell Lymphoma
NCT00091559Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2005
- Primary completion
- Nov 2005
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in cutaneous T-cell lymphoma (CTCL), sponsored by Merck & Co. Primary endpoint: Objective Response Rate. Started Feb 2005; status: completed.
02
Drugs
vorinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00091559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091559.